podophyllotoxin has been researched along with panobinostat in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Agarwal, P; Atadja, P; Axelson, M; De Bruyne, E; Fristedt, C; Jernberg-Wiklund, H; Larsson, O; Lemaire, M; Menu, E; Österborg, A; Van Camp, B; Van Valckenborgh, E; Vanderkerken, K | 1 |
1 other study(ies) available for podophyllotoxin and panobinostat
Article | Year |
---|---|
The HDAC inhibitor LBH589 enhances the antimyeloma effects of the IGF-1RTK inhibitor picropodophyllin.
Topics: Animals; Apoptosis; Caspase 8; Cell Adhesion; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; G2 Phase Cell Cycle Checkpoints; Gene Expression Profiling; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Mice; Mice, Inbred C57BL; Multiple Myeloma; Panobinostat; Podophyllotoxin; Receptor, IGF Type 1; Transcriptome; Tumor Cells, Cultured | 2012 |